Roles of ABCC1 and ABCC4 in Proliferation and Migration of Breast Cancer Cell Lines by Low, Floren G. et al.
 International Journal of 
Molecular Sciences
Article
Roles of ABCC1 and ABCC4 in Proliferation and
Migration of Breast Cancer Cell Lines
Floren G. Low, Kiran Shabir , James E. Brown, Roslyn M. Bill and Alice J. Rothnie *
College of Health & Life Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK;
low_guy@hotmail.com (F.G.L.); shabirk@aston.ac.uk (K.S.); j.e.p.brown@aston.ac.uk (J.E.B.);
R.M.Bill@aston.ac.uk (R.M.B.)
* Correspondence: a.rothnie@aston.ac.uk
Received: 18 September 2020; Accepted: 7 October 2020; Published: 16 October 2020


Abstract: ABCC1 and ABCC4 utilize energy from ATP hydrolysis to transport many different
molecules, including drugs, out of the cell and, as such, have been implicated in causing drug resistance.
However recently, because of their ability to transport signaling molecules and inflammatory
mediators, it has been proposed that ABCC1 and ABCC4 may play a role in the hallmarks of
cancer development and progression, independent of their drug efflux capabilities. Breast cancer
is the most common cancer affecting women. In this study, the aim was to investigate whether
ABCC1 or ABCC4 play a role in the proliferation or migration of breast cancer cell lines MCF-7
(luminal-type, receptor-positive) and MDA-MB-231 (basal-type, triple-negative). The effects of small
molecule inhibitors or siRNA-mediated knockdown of ABCC1 or ABCCC4 were measured. Colony
formation assays were used to assess the clonogenic capacity, MTT assays to measure the proliferation,
and scratch assays and Transwell assays to monitor the cellular migration. The results showed a
role for ABCC1 in cellular proliferation, whilst ABCC4 appeared to be more important for cellular
migration. ELISA studies implicated cAMP and/or sphingosine-1-phosphate efflux in the mechanism
by which these transporters mediate their effects. However, this needs to be investigated further, as it
is key to understand the mechanisms before they can be considered as targets for treatment.
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1. Introduction
Breast cancer is the most common cancer in women, affecting more than two million women
worldwide per year [1]. The development of new targeted therapeutics and the encouragement of
women to carry out early screening programs have significantly improved survival rates in the Western
world [2–5]. Breast cancers that express the estrogen receptor and/or the progesterone receptor can be
treated with receptor-blocking hormone therapy or with aromatase inhibitors to decrease the levels of
estrogen produced [6,7]. Cancers that have high expression of human epidermal growth factor receptor
2 (HER2) can be treated with monoclonal antibodies, which bind to the receptor and block it [7].
However, some breast cancers, termed triple-negative, do not express any of these receptors, and thus,
the only treatment available is conventional chemotherapy. Triple-negative breast cancers make up
around 10–15% of all breast cancer cases [8], are typically aggressive, and show high levels of metastases
and mortality [9,10]. The development of metastasis and/or cancers becoming resistant to therapeutic
agents is a growing problem. Women diagnosed at an early stage of breast cancer may have recurrent
disease, and at least a quarter of all cases may develop a resistance to therapeutic treatments [2].
Moreover, with the increase in disease progression, the incidence of therapeutic resistance becomes
more alarming.
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One common cause of therapeutic resistance in breast cancer is the efflux of drugs by membrane
proteins of the ATP-binding cassette (ABC) transporter family of proteins [11,12]. ABCC1 (multidrug
resistance protein 1/MRP1) and ABCC4 (multidrug resistance protein 4/MRP4) are two members of the
C subfamily of ABC transporters that are capable of effluxing several different chemotherapeutic drugs
out of cancer cells [13–15]. Previous studies have shown that ABCC1 expression is a negative prognostic
marker, associated with a decreased survival rate in breast cancer patients [16–18] and an increased risk
of relapse [19]. Following chemotherapeutic treatment, the expression of ABCC1 in breast cancer tumors
was found to increase [20], and its expression level was shown to be highest in the most aggressive
subtypes of breast cancers [18]. ABCC4 expression is similarly upregulated in chemotherapy-treated
breast tumors compared to noncancerous tissue [21], and ABCC4 polymorphisms are linked with the
response to aromatase inhibitors for estrogen-receptor-positive breast cancer [22].
However, it has been proposed that ABCC1 and ABCC4 may play a role in the hallmarks of
cancer development and progression, independent of their drug efflux capabilities [23]. This is because
ABCC1 and ABCC4 are capable of transporting numerous physiological substrates and have roles
in metabolism and inflammation [13,24,25]. For example, ABCC1 can transport glutathione and
inflammatory mediators such as leukotrienes and prostaglandins, as well as the bioactive lipids
sphingosine-1-phosphate (S1P) and lysophosphatidyl inositol (LPI), which are implicated in cell
proliferation, migration, and invasion [26–31]. ABCC4 can efflux the cyclic nucleotides cAMP and
cGMP involved in cellular signaling, as well as leukotrienes, prostaglandins, and thromboxanes and
S1P [32–38]. Studies on neuroblastoma (a rare childhood cancer) have confirmed that both ABCC1 and
ABCC4 play an important physiological role in its development, independent of their role in multidrug
resistance, affecting cellular proliferation, migration, and differentiation [39]. ABCC4 has also been
implicated in cancer cell proliferation in leukemia [40,41], gastric cancer [42], lung cancer [43], renal
cancer [44], ovarian cancer [45], and pancreatic cancer [46,47]. However, less is known about whether
ABCC1 and ABCC4 have a role in breast cancer development and/or progression.
In this study, the role of ABCC1 and ABCC4 in breast cancer progression was investigated.
The breast cancer cell lines MDA-MB-231 and MCF-7 were used. Both are considered to be aggressive,
but MCF-7 is a luminal-type breast cancer with the presence of progesterone, estrogen, and human
epidermal growth factor 2 (HER2) receptors, whereas MDA-MB-231 is a basal-type triple-negative cell
line. The effect of small molecules inhibitors or siRNA knockdown of ABCC1 and ABCC4 on cellular
proliferation, clonogenic capacity, cell migration, and invasion were investigated.
2. Results
2.1. Expression of ABCC1 and ABCC4 in Breast Cancer Cell Lines
In order to determine whether the breast cancer cell lines expressed ABCC1 or ABCC4, membrane
extracts were prepared and assayed via Western blot, as shown in Figure 1. It can be seen that both
MCF-7 and MDA-MB-231 cells express both ABCC1 and ABCC4, with the level of expression of the
two transporters being higher in the MDA-MB-231 cells than in the MCF-7 cells. In addition, the cell
lines were tested for the well-known multidrug resistance transporters P-glycoprotein/ABCB1 and
ABCG2 (Figure S1). Only the MCF-7 cell line showed significant expression of these two transporters.
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Figure 1. ABCC1 and ABCC4 are both expressed in MCF-7 and MDA-MB-231 breast cancer cells. 
Membrane extracts (80 μg protein/well) from MCF-7 and MDA-MB-231 cells were assayed by 
Western blot for the expression of (a) ABCC1 or (b) ABCC4, alongside Hela cells as a positive control. 
ABCC1 was detected using the anti-MRP1 EPR4658 antibody (1:1000). ABCC4 was detected using the 
anti-ABCC4 M4I-10 antibody (1:100). The blue arrow indicates the band corresponding to ABCC1 (a) 
or ABCC4 (b). Comparable sample loading was monitored afterwards using the anti-tubulin primary 
antibody. Uncropped images can be found in Figure S3. 
2.2. The Effect of ABCC Small Molecule Inhibitors on Breast Cancer Cell Proliferation 
Having established that both cell lines expressed the ABCC proteins, we investigated the effect 
of small molecule inhibitors of these proteins on the ability of the cells to proliferate. The small 
molecule inhibitors used in the study are detailed in Table 1. 
Table 1. ABCC inhibitors used in this study. 
Inhibitor Inhibits ABCC1 Inhibits ABCC4 Reference 
MK571 √ √ [48–50] 
Reversan √  [51] 
Ceefourin 1  √ [52] 
Ceefourin 2  √ [52] 
Indomethacin  √ [33,53] 
The first parameter investigated was the clonogenic capacity of the cells, i.e., the ability to 
reproduce from a single cell. Examples of the assay are shown in Figure 2a,b, where it can be seen 
that, following the treatment of MDA-MB-231 cells with MK571 or Reversan, at increasing 
Figure 1. ABCC1 and ABCC4 are both expressed in MCF-7 and MDA-MB-231 breast cancer cells.
Membrane extracts (80 µg protein/well) from MCF-7 and MDA- B-231 cells were assayed by Western
blot for the expression of (a) ABCC1 or (b) ABCC4, alongside Hela cells as a positive control. ABCC1 was
detected using the anti-MRP1 EPR4658 antibody (1:1000). ABCC4 was detected using the anti-ABCC4
M4I-10 antibody (1:100). The blue arrow indicates the band corresponding to ABCC1 (a) or ABCC4
(b). Comparable sample lo ding was mo itored afterwards using the anti-tub lin pri antibody.
Uncropped images can be found in Figure S3.
2.2. The Effect of ABCC Small Molecule Inhibitors on Breast Cancer Cell Proliferation
Having established that both cell lines expressed the ABCC proteins, we investigated the effect of
small molecule inhibitors of these proteins on the ability of the cells to proliferate. The small molecule
inhibitors used in the study are detailed in Table 1.
Table 1. ABCC inhibitors used in this study.
Inhibitor Inhibits ABCC1 Inhibits ABCC4 Reference
MK571
√ √
[48–50]
Reversan
√
[51]
Ceefourin 1
√
[52]
Ceefourin 2
√
[52]
Indomethacin
√
[33,53]
The first parameter investigated was the clonogenic capacity of the cells, i.e., the ability to
reproduce from a single cell. Examples of the assay are shown in Figure 2a,b, where it can be seen that,
following the treatment of MDA-MB-231 cells with MK571 or Reversan, at increasing concentrations,
both the number of colonies formed over seven days and the size of those colonies are reduced.
The average data shown in Figure 2c–e show that Reversan and MK571 affect the colony formation
for both MDA-MB-231 and MCF-7 cells, but the effect is more pronounced for the MDA-MB-231
cells, perhaps correlating with the higher level of ABCC protein expression in these cells. In contrast,
Ceefourin 1 and 2 and Indomethacin had no effect at all on the colony formation.
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Figure 2. MK571 and Reversan affect the clonogenic capacity of breast cancer cells. 100 cells/well were 
seeded in 6-well plates and cultured at 37 °C for 24 h, after which cells were treated with the indicated 
concentrations of inhibitors. Control wells were untreated cells. After 7 days of culture, the colonies 
formed were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet, the colonies 
Figure 2. MK571 and Reversan affect the clonogenic capacity of breast cancer cells. 100 cells/well were
seeded in 6-well plates and cultured at 37 ◦C for 24 h, after which cells were treated with the indicated
concentrations of inhibitors. Control wells were untreated cells. After 7 days of culture, the colonies
formed were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet, the colonies counted
and measured. Example results for MDA-MB-231 cells treated with (a) MK571 or (b) Reversan. Average
results for the number (c,d) and size (e,f) of colonies for MCF-7 cells (c,e) and MDA-MB-231 (d,f).
Data are mean ± sem, n ≥ 6. Data were analyzed using a one-way ANOVA with a Dunnett’s post hoc
test; * p < 0.05, *** p < 0.001, and **** p < 0.0001 significantly lower than the untreated sample.
The effect of these inhibitors on cellular proliferation was also investigated using an MTT assay.
As can be seen in Figure 3, the presence of the inhibitors did not affect the proliferation of either cell
line for the first 24 h. However, after this time, MK571 and Reversan had a significant impact on the
proliferation of both MCF-7 and MDA-MB-231 cells, whereas Ceefourin 1 and 2 and Indomethacin
did not. To confirm the results obtained with the MTT assay, and to make sure it was not due to an
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indirect effect on the enzyme required to reduce MTT, proliferation was also measured by a trypan blue
exclusion and cell counting approach (Figure S2). Although the errors are larger using this approach,
the key findings replicate those of the MTT assay.
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2.3. Effect of Inhibitors on Breast Cancer Cell Migration 
In addition to rapid proliferation, enhanced migration is a hallmark of aggressive cancers. 
Therefore, the effects of ABCC inhibitors on breast cancer cell migration was measured using a 
scratch assay, as shown in Figure 4a. The MDA-MB-231 cells migrated faster than the MCF-7 cells 
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Figure 3. MK571 and Reversan affect the proliferation of breast cancer cells. Fifteen thousand MCF-7
cells (a,b) or 6000 MDA-MB-231 cells (c,d) were seeded in 24-well plates. After 4 h of culture, cells were
treated with inhibitors, as detailed. Cell viability was assessed at 6, 12, 24, 48, and 72 h after treatment
using an MTT assay and absorbance measured at 570 nm. Data are mean ± SD, n ≥ 6. Data were
analyzed using a two-way ANOVA with a Dunnett’s post hoc test. *** p < 0.001 and **** p < 0.0001
significantly lower than the untreated sample.
2.3. Effect of Inhibitors on Breast Cancer Cell Migration
In addition to rapid proliferation, enhanced migration is a hallmark of aggressive cancers.
Therefore, the effects of ABCC inhibitors on breast cancer cell migration was measured using a scratch
assay, as shown in Figure 4a. The MDA-MB-231 cells migrated faster than the MCF-7 cells (Figure 4b,c).
Most of the inhibit r treatments had no sig ificant effect on the migration. However, the tr atment
with MK571 did significantly decrease the migration of MDA-MB-231 cells (Figure 4c). This was not
due to an effect on proliferation, si ce after 10–12 h when he migration was most affected, no effect on
the proliferation was observed (Figure 3c).
MK571, which inhibits both ABCC1 and ABCC4, and Reversan, which inhibits ABCC1, were the
only inhibitors to affect the proliferation of the breast cancer cells. MK571 was the only drug to affect the
cell migration. Ceefourin 1 and 2 and Indomethacin, which inhibit ABCC4, had no effects. This might
suggest that ABCC1 plays a role in the proliferation of breast cancer cells. Similarly, it might suggest
that ABCC1, or maybe both ABCC1 and ABCC4 together, are involved in the migration. However,
one of the challenges associated with using inhibitors of multidrug transporters is the lack of specificity.
In addition to inhibiting ABCC1 and ABCC4, MK571 can inhibit other ABCC family members, and it is
also a leukotriene antagonist, inhibiting the binding of leukotriene D4 (LTD4) to cysteinyl leukotriene
receptor 1 [50]. Reversan is an inhibitor of ABCC1 but can also inhibit the related protein ABCB1 [54].
Indomethacin inhibits ABCC4 but was developed as an inhibitor of cyclooxygenase. Therefore,
the effect of the genetic knockdown of ABCC1 and ABCC4 was investigated.
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Figure 4. MK571 decreases the rate of migration by MDA-MB-231 cells. Cells were seeded in 24-well
plates to reach 100% confluency the day of the assay. A scratch across the monolayer of the cells was
carefully made, and the medium was replaced with fresh prewarmed culture medium. Cells were
treated with the inhibitors as described above. Three image positions were selected from each well,
and images were taken at 1-h intervals using the Cell-IQ. Representative images of MDA-MB-231
scratch assay (a). Pink lines represent the scratch edges as defined by the Cell IQ software, and the blue
lines are the distance measurement between the edges. Average results for MCF-7 (b) and MDA-MB-231
(c) cell migration in the presence of inhibitors. Data are mean ± sem, n ≥ 6. Data were analyzed
using a two-way ANOVA with a Dunnett’s post hoc test. * p < 0.05 significantly lower than the
untreated sample.
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2.4. Knockdown of ABCC1 and ABCC4 Using siRNA
Knockdown of ABCC1 and ABCC4 was carried out using siRNA. Two different siRNA sequences
for each protein were tested, alongside a negative siRNA. The effectiveness of the knockdown was
measured by both RT-qPCR to monitor the mRNA levels and Western blotting to monitor the protein
levels. As can be seen in Figure 5, the knockdown of either ABCC1 or ABCC4 was effective in both cell
lines. In addition, since the two proteins have overlapping substrate specificity, the dual knockdown
of both proteins was also undertaken (Figure 5e).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 21 
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Figure 5. ABCC1 and ABCC4 can be successfully knocked down in breast cancer cells using siRNA.
Gene knockdown in breast cancer cells was performed using the INTERFERin-siRNA transfection
protocol, with two different ABCC1 siRNAs (#30 or #31), two different ABCC4 siRNAs (#34 or #35),
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or in combination (#30/#34 or #31/#35). A negative control siRNA was also used. The effectiveness
of the knockdown was measured by both RT-qPCR and Western blotting. (a) Knockdown of ABCC1
in MCF-7 cells, (b) knockdown of ABCC4 in MCF-7 cells, (c) knockdown of ABCC1 in MDA-MB-231
cells, (d) knockdown of ABCC4 in MDA-MB231 cells and (e) double knockdown of both transporters
in each cell line. Uncropped images can be found in Figure S4. RT-qPCR data are mean ± sem, n = 3.
Data were analyzed using a one-way ANOVA with a Dunnett’s post hoc test. * p < 0.05 and ** p < 0.01
significantly lower than the negative siRNA sample.
2.5. The Effect of ABCC1 and ABCC4 Knockdown on Breast Cancer Proliferation and Migration
Having established that the ABCC proteins could be knocked down, the effect of this on cell
proliferation was investigated. In Figure 6a, it can be seen that one of the knockdowns of ABCC1 in
MCF-7 cells caused a decrease in clonogenic capacity. The double knockdown of both ABCC1 and
ABCC4 caused an even larger impact. For MDA-MB-231 cells, only one of the double knockdowns had
a significant effect (Figure 6b). In contrast, when examining the bulk proliferation, it can be seen in
Figure 6c,d that knockdown had no significant effect on the growth of either cell line.
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Figure 6. Combined knockdown of ABCC1 and ABCC4 affects the clonogenic capacity of breast cancer
cells. (a,b) Clonogenic capacity of breast cancer cells following the siRNA-mediated knockdown of
ABCC1 or ABCC4 was analyzed using a colony formation assay. (c,d) Proliferation of breast cancer
cells following the siRNA-mediated knockdown of ABCC1 or ABCC4 was analyzed using an MTT
assay. Data are mean ± sem, n ≥ 6. Data were analyzed by an ANOVA with a Dunnett’s post hoc
test. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001significantly lower than with the negative
siRNA treatment.
Next, the effect of ABCC knockdown on cell migration was investigated. Figure 7a,b shows the
average results from the scratch assays. ith the CF-7 cells (Figure 7a), a knockdown with ABCC4
siRNA #35 caused a significant decrease i i rati , and with the MDA-MB-231 cells (Figure 7b),
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both ABCC4 knockdowns caused a significant decrease in migration. To examine this further, invasion
rather than just migration was investigated (Figure 7c,d). With the MCF-7 cells, no significant effects
were observed; however, with MDA-MB-231 cells, the knockdown with ABCC4 siRNA #35 and one of
the double knockdowns did cause a significant decrease in invasion.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 10 of 21 
 
 
Figure 7. siRNA knockdown of ABCC4 affects the migration of breast cancer cells. (a,b) Migration of 
breast cancer cells following the siRNA-mediated knockdown of ABCC1 or ABCC4 was analyzed 
using a scratch assay. Data are mean ± sem, n ≥ 9. (c,d) Migration of breast cancer cells following the 
siRNA-mediated knockdown of ABCC1 or ABCC4 was also investigated using a cellular invasion 
assay. Data are mean ± sem, n ≥ 3. Data were analyzed by an ANOVA with a Dunnett’s post hoc test. 
* p < 0.05, ** p < 0.01, and *** p < 0.001 significantly lower than with the negative siRNA treatment. 
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mediators such as S1P and LPI. It has previously been proposed that ABCC1 is involved in creating 
a feedback signaling loop with the G protein-coupled receptor, GPR55, whereby ABCC1 exports LPI, 
which binds to GPR55 and activates it, leading to downstream signaling and increased proliferation 
[31]. Therefore, we measured the expression of GPR55 in the breast cancer cell lines by Western blot 
(Figure 8a). GPR55 is indeed expressed in the MDA-MB-231 cells; however, there was little, if any, 
expression in the MCF-7 cells. Since the effects we observed with ABCC1 and ABCC4 inhibitors and 
knockdown were with both cell lines, this would argue against it being due to LPI export and GPR55 
activation. 
Next, the efflux of cAMP was investigated as a potential mechanism, as ABCC4 is capable of 
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The concentration of cAMP in the medium from MCF-7 cells was outside the standard range and, 
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Figure 7. siRNA knockdown of ABCC4 affects the migration of breast cancer cells. (a,b) Migration
of breast cancer cells following the siRNA-mediated knockdown of ABCC1 or ABCC4 was analyzed
using a scratch assay. Data are mean ± sem, n ≥ 9. (c,d) Migration of breast cancer cells following the
siRNA-mediated knockdown of ABCC1 or ABCC4 was also investigated using a cellular invasion
assay. Data are mean ± sem, n ≥ 3. Data were analyzed by an ANOVA with a Dunnett’s post hoc test.
* p < 0.05, ** p < 0.01, and *** p < 0.001 significantly lower than with the negative siRNA treatment.
These results with the ABCC knockdowns correlate well with the inhibitor studies, with ABCC1
and the double knockdown having an impact on cellular proliferation, whilst ABCC4 and the double
knockdown affect migration.
2.6. Investigation into Potential Mechanisms by Which ABCC Transporters Affect Cellular
Proliferation or M gration
ABCC1 and ABCC4 both transport a wide array of different molecules with the potential to impact
cellular proliferation and migration, including cyclic nucleotid s, eic sanoids, and lipid m di tors
such as S1P and LPI. It has previously been proposed that ABCC1 is involved n creat ng a feedback
signaling loop with the G protein-coupled receptor, GPR55, wh reby ABC 1 exports LPI, whi h binds
to GPR55 and act vates it, leading to downstream signaling and increased proliferation [31]. Therefore,
e measured the expression of GPR55 in the breast cancer c ll lines by Western blot (Figure 8a). GPR55
is indeed xpr ssed in the MDA-MB-231 cells; however, there was little, if any, expression in th MCF-7
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cells. Since the effects we observed with ABCC1 and ABCC4 inhibitors and knockdown were with
both cell lines, this would argue against it being due to LPI export and GPR55 activation.
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mediates an effect [33]. An ELISA was used to measure Prostaglandin E2 (PGE2) levels in the cell 
medium. The concentration of PGE2 in the medium from MDA-MB-231 cells was outside the range 
of standards used and, thus, could not be reliably measured. The concentration of PGE2 in the 
medium from MCF-7 cells can be seen in Figure 8c. Neither the knockdown of ABCC proteins nor 
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Figure 8. Efflux of cAMP or S1P are possible mechanisms by which ABCC transporters affect breast
cancer cells. (a) Western blot analysis of the expression of GPR55 in breast cancer cell lines. The blue
arrow indicates the band corresponding to GPR55 (b) Efflux of cAMP from MDA-MB-231 breast
cancer cells was assayed using an ELISA. Data are mean ± sem, n ≥ 2, each in duplicate. (c) Efflux of
Prostaglandin E2 (PGE2) from MCF-7 breast cancer cells was assayed using an ELISA. Data are mean
± sem, n ≥ 2, each in duplicate. (d) Efflux of S1P from MDA-MB-231 breast cancer cells was assayed
using an ELISA. Data are mean ± sem, n ≥ 3, each in duplicate. Data were analyzed by a one-way
ANOVA with a Dunnett’s post hoc test. * p < 0.05 and ** p < 0.01, significantly lower than untreated or
negative siRNA treatment.
Next, the efflux of cAMP was investigated as a potential mechanism, as ABCC4 is capable of
effluxing cyclic nucleotides [32]. An ELISA was used to assay cAMP in the cell medium (Figure 8b).
The concentration of cAMP in the medium from MCF-7 cells was outside the standard range and,
therefore, could not be reliably measured. For MDA-MB-231, the knockdown of ABCC1 had no
significant effect on the concentration of cAMP in the medium, which is unsurprising, as ABCC1 is
not reported to transport cyclic nucleotides. However, the knockdown with ABCC4 siRNA #35 did
significantly decrease the concentration of cAMP in the medium, as did the treatment with MK571.
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An efflux of eicosanoids such as prostaglandins could be another possible way in which ABCC4
mediates an effect [33]. An ELISA was used to measure Prostaglandin E2 (PGE2) levels in the cell
medium. The concentration of PGE2 in the medium from MDA-MB-231 cells was outside the range of
standards used and, thus, could not be reliably measured. The concentration of PGE2 in the medium
from MCF-7 cells can be seen in Figure 8c. Neither the knockdown of ABCC proteins nor the treatment
with MK571 had any effect on the levels of PGE2 measured.
Finally, S1P was investigated, as there are reports that both ABCC1 and ABCC4 are capable of
transporting S1P [29,38]. Figure 8d shows the results of the S1P ELISA. Only the MDA-MB-231 cells
effluxed sufficient S1P for reliable measurement. Although none of the siRNA knockdown samples
showed any significant difference in S1P concentrations, the treatment with MK571, which inhibits
both ABCC1 and ABCC4, did significantly decrease the amount of S1P in the medium.
3. Discussion
ABCC1 and ABCC4 have previously been implicated as negative prognostic indicators for breast
cancer [16–19,22]. This may be due to their ability to export chemotherapeutic drugs, leading to
multidrug resistance [13–21]. However, ABCC1 and ABCC4 can also transport a wide range of
substrates involved in inflammation and cellular signaling and have been shown in several different
cancer types to have a role in cancer development and progression that is independent of drug
resistance [39–47,55]. Therefore, in this study, we investigated whether ABCC1 or ABCC4 are involved
in cellular proliferation or migration in breast cancer cell lines. We found that both MCF-7 and
MDA-MB-231 cells expressed both ABCC1 and ABCC4, with MDA-MB-231 cells having a higher
expression of both transporters, which is in agreement with previous studies [56,57]. MDA-MB-231
cells are basal-type triple-negative and often reported as more aggressive than MCF-7 cells, so this
would correlate with the expression levels observed. It has been reported that ABCC1 is frequently
expressed in lymph node metastases of breast cancer patients and that MRP1 expression is more
pronounced in lymph node metastases than in corresponding primary tumors [58].
Using both small molecule inhibitors and siRNA knockdown of ABCC1 and ABCC4,
we investigated the impact of these transporters on the proliferation, clonogenic capacity, migration,
and invasion of the breast cancer cell lines. MK571, which inhibits both ABCC1 and ABCC4,
and Reversan, which inhibits ABCC1, both had significant effects on the proliferation and clonogenic
capacity of MCF-7 and MDA-MB-231 cells, suggesting a role for ABCC1 or both transporters in cellular
proliferation. Similarly, one of the ABCC1 knockdowns and the double ABCC1/ABCC4 knockdowns
decreased the colony formation with MCF-7 cells, although only one of the double knockdowns
affected colony formation in the MDA-MB-231 cells. It should be noted that MK571 not only inhibits
ABCC1 and ABCC4 but, also, other members of the ABCC family, and it is a leukotriene antagonist,
inhibiting the binding of LTD4 to the cysteinyl leukotriene receptor 1 [50], which could also impact cell
signaling. However, the similar results obtained with the knockdowns would argue that the effects
observed are due to ABCC1/ABCC4. Similarly, Reversan is also able to inhibit the related protein
ABCB1, but given that Reversan affected both cell lines, and only the MCF-7 cells showed a significant
expression of ABCB1 (Figure S1), it is unlikely this is the cause. That knockdown of ABCC1 alone did
not affect the colony formation of MDA-MB-231 cells, and only one of the double knockdowns affected
it, maybe because of the higher expression level of the transporters in MDA-MB-231 cells. The siRNA
method only results in knockdown, not knockout, as seen in Figure 5. Although the protein levels are
decreased in MDA-MB-231 cells, they were higher to start with, so it is possible that sufficient protein
remains even after knockdown. Furthermore, siRNA knockdown is only transient, and it is not known
if all cells were affected or just a proportion of them. We chose to use siRNA, because with complete
knockdowns, the overexpression of other ABC transporters often occurs to compensate. In the future,
perhaps the use of lentiviral shRNA could be investigated [42,43,46].
When investigating cellular migration, only MK571 had a significant effect, and only with
the MDA-MB-231 cells, suggesting perhaps that the dual inhibition of both ABCC1 and ABCC4
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was important. However, the siRNA knockdowns showed that the ABCC4 knockdown affected
migration in both cell lines. Why the reportedly specific ABCC4 inhibitors, Ceefourin 1 and Ceefourin
2 [52], did not cause any effect on the cellular migration, when ABCC4 knockdown did, is not clear.
The cellular invasion assays were more variable but, again, showed an effect of ABCC4 knockdown in
MDA-MB-231 cells.
Our results suggest that ABCC1 is important for breast cancer proliferation, whilst ABCC4 has a
greater role in cellular migration and invasion (Table 2). This contrasts with a study investigating the
role of these transporters in neuroblastoma, where ABCC4 was more associated with proliferation
and ABCC1 with migration [39]. Similarly, in pancreatic cancer, ABCC4 was associated with
proliferation [47]. However, in epithelial ovarian cancer, ABCC4 was associated with proliferation,
migration, and invasion [45]. In agreement with our results, breast cancer cells overexpressing ABCC1
showed an increase in proliferation, which could be inhibited by MK571, and overexpression of ABCC1
enhanced tumor growth in mice [59]. Additionally, mice implanted with breast cancer tumors with
varying levels of ABCC4 expression showed no differences in tumor growth, but an increased ABCC4
expression was associated with increased metastases [56]. Therefore, the role(s) played by these
transporters is not necessarily the same across different cancers, but within breast cancers, our results
appear to agree with other studies in the literature. It should also be noted that, although the current
study only investigated ABCC1 and ABCC4, they are not necessarily the only important transporters.
In neuroblastoma, ABCC3 was shown to be very important, albeit as a positive prognostic indicator [39].
In contrast, ABCC3 was implicated in breast cancer stem-like features [20]. ABCC11 has also been
implicated in aggressive breast cancer and prognosis [18].
Table 2. Summary of findings. ↓ significant decrease. — no significant effect. n/d not determined.
Condition ClonogenicCapacity Proliferation Migration Invasion
Comparable
Findings in the
Literature
ABCC1 inhibition ↓ ↓ — n/d [59]
ABCC4 inhibition — — — n/d
Double inhibition ↓ ↓ ↓ n/d [59]
ABCC1 knockdown ↓ — — — [59]
ABCC4 knockdown — — ↓ ↓ [56]
Double knockdown ↓ — n/d ↓
Understanding the mechanism by which these transporters mediate their effects is important.
Both transporters are able to efflux a wide range of different molecules. It is important to know
what molecule is being effluxed that causes the effects observed. It might be that targeting the ABC
transporters themselves is not the best approach, as they have historically proven difficult to target,
often because they have so many important roles. Instead, understanding the pathway they are
involved with and targeting something earlier or later in the signaling pathway might be a more
effective approach. Therefore, preliminary investigations into how ABCC1 and/or ABCC4 might elicit
their effects on breast cancer cell proliferation and migration were undertaken. ABCC1 has previously
been linked to GPR55 in a feedback loop, where ABCC1 exports LPI, which binds to and activates
GPR55, leading to downstream signaling, and this was implicated as important for prostate and
ovarian cancer cell proliferation [31]. However, we found little/no expression of GPR55 within MCF-7
cells. Given that ABCC1 inhibition or knockdown affected the proliferation and clonogenic capacity of
MCF-7 cells, this would argue against LPI export and GPR55 activation being a key feature to explain
our findings. The export of cAMP was a second method explored, as ABCC4 is known to be able
to efflux cyclic nucleotides [32]. The knockdown of ABCC4 or inhibition with MK571 significantly
decreased the amount of cAMP effluxed from MBA-MB231 cells. This agrees well with a previous
study [57], and it has been suggested that increasing cellular cAMP levels is a potential method of
combatting triple-negative breast cancer [57,60]. The export of PGE2 has also been suggested as a
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potential mechanism by which ABCC4 might be important in breast cancer [61]. In our study, the levels
of PGE2 exported by MDA-MB-231 cells were too high to quantify accurately. With MCF-7 cells,
no effect of ABCC1/ABCC4 knockdown or inhibition was observed. Similarly, no effect of ABCC4
overexpression on the PGE2 efflux from MCF-7 cells was observed previously [56]. However, the same
report suggests that the knockdown of ABCC4 in MBA-MB-231 cells does decrease the PGE2 efflux and
that this is important for breast cancer metastasis [56]. Given that we observed the effects of ABCC4
knockdown on the migration of both MCF-7 and MDA-MB-231 cells, this might argue that it is not
due simply to PGE2 efflux; however, further investigation with MDA-MB-231 cells is needed. Finally,
we investigated the efflux of S1P, as levels of S1P have previously been implicated in breast cancer [62],
and both ABCC1 and ABCC4 are capable of transporting S1P [29,38]. Although the knockdown of
ABCC1 or ABCC4 did not show a significant effect on extracellular levels of S1P, the inhibition of
both ABCC1 and ABCC4 with MK571 did decrease the amount of S1P effluxed. This result agrees
with a previous study that also observed a decreased S1P efflux from MCF-7 cells in the presence of
MK571 [63]. The same study also showed that siRNA knockdown of ABCC1 decreased the amount
of S1P exported from MCF-7 cells, but a large effect was only seen when the cells were stimulated
with estradiol, which we did not do, and this might explain why we see no effects of ABCC1 or
ABCC4 knockdown.
4. Materials and Methods
4.1. Cell Culture
The MDA-MB-231 and MCF-7 human breast cancer cells were originally obtained from ATCC.
They were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Lonza, Slough, UK) containing
4.5-g/L glucose and L-glutamine supplemented with 10% v/v fetal bovine serum (FBS) (Gibco®,
ThermoFisher Scientific, Loughborough, UK) and 100-U/mL penicillin and 0.1-mg/mL streptomycin
(sterile-filtered penicillin-streptomycin solution 100×, Biowest, Nuaillé, France). Cells were cultured in
an environment of 95% air and 5% CO2 at 37 ◦C.
4.2. Colony Formation Assay
Cell growth from a single cell was determined using the colony formation assay, as described
previously [39,64]. Briefly, 100 cells/well were seeded in 6-well plates and cultured at 37 ◦C for 24 h,
after which cells were treated with MK571 (Merck Life Science, Gillingham, UK), indomethacin (Merck),
Reversan (Tocris Bioscience, Abingdon, UK), Ceefourin 1, or Ceefourin 2 (Abcam, Cambridge, UK).
Control wells were untreated cells. After 7 days of culture, the colonies formed were fixed with 4%
paraformaldehyde and stained with 0.1% crystal violet. Wells were left to dry in open air at room
temperature, and visible colonies of 50 cells or more were manually counted under a light box using a
transparent film and a fine marker. The sizes of the colonies were measured using ImageJ 1.52 (NIH,
Bethesda, MD, USA).
4.3. Cell Proliferation Assays
Cell viability was analyzed using a standard MTT assay. Fifteen thousand MCF-7 cells or 6000
MDA-MB-231 cells were plated in each well of a 24-well plate in a total volume of 400µL of culture
medium. After 4 h of culture, cells were treated with inhibitors, as described above. The cell viability
was assessed at 6, 12, 24, 48, and 72 h after treatment. Forty microliters of MTT (5 mg/mL) was added
to each well and further incubated for 1 h at 37 ◦C. Wells were left to dry at 37 ◦C, and 400 µL of DMSO
(dimethylsulfoxide) was added and left at 37 ◦C for 10 min. One hundred microliters of DMSO from
each well was transferred to 96-well plates in triplicates. The absorbance values were read at 570 nm
using a Multiskan™ GO microplate spectrophotometer (Thermo Fisher Scientific, Gillingham, UK).
Alternatively, at the given time points after treatment, the cells were harvested, diluted in trypan
blue at a ratio of 1:4, viewed using a hemocytometer and microscope, and counted manually.
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4.4. Cell Migration Assays
Cell migration was assessed using the Cell IQ (CM Technologies—intelligent cell analysis, Tampere,
Finland) scratch assay. Cells were seeded in 24-well plates to reach 100% confluency the day of the
assay. A scratch across the monolayer of the cells was carefully made using a 10-µL pipette tip, and the
media was replaced with fresh prewarmed culture medium. Cells were treated with the inhibitors,
as described above. Three image positions were selected from each well, and images were taken at 1-h
intervals. Images were analyzed using the Cell-IQ analysis software (CM Technologies).
4.5. Cell Invasion Assays
The 24-well plate Transwell inserts (pore size 8 µm, translucent) (Greiner bio-one, Stonehouse,
UK) were coated with 30 µL of ice-cold Matrigel (Corning, VWR, Lutterworth, UK) mixed with cold
serum-free medium at a ratio of 1:3. The coated Transwell inserts were left to set at 37 ◦C for 2 h.
Fifty thousand cells were seeded in each Transwell insert suspended in 300 µL of 0.5% v/v FBS culture
medium. Eight hundred microliters of chemoattractant (10% v/v FBS cell culture medium) was added
to the wells, and the Transwell inserts were placed in each of the wells that contain a chemoattractant.
The Transwell inserts were incubated for 24 h at 37 ◦C. After 24 h, the culture medium in the Transwell
inserts were discarded, and a cotton swab moistened with Dulbecco’s phosphate-buffered saline
(DPBS) (Biowest) was used to, gently but putting firm pressure, rub the inside of the Transwell inserts
to remove cells, and this process was repeated with a second cotton swab. The cells that moved to
the lower surface of the membrane of the Transwell inserts were stained with Differential Quik stain
(Modified Giemsa) (Generon, Slough, UK), following the manufacturer’s instructions. The Transwell
inserts were then rinsed twice with water. A cotton swab moistened with DPBS was used to gently but
putting firm pressure wipe again the inside of the Transwell inserts to rid of any cells left. The Transwell
inserts were left to dry at room temperature. To determine the percentage cell invasion, the invaded
cells were counted from randomly selected five fields of view for each Transwell insert under a light
microscope at a magnification of ×40, and the mean number of invaded cells were obtained.
4.6. Gene Knockdown
Gene knockdown was performed following the INTERFERin-siRNA transfection protocol
(Polyplus Transfection, Illkirch, France). Briefly, 25,000 cells were seeded in 24-well plates the
day before transfection, ensuring 30–50% confluency at the time of transfection. The siRNA transfection
complexes were added to cells dropwise and left to incubate for 3 days at 37 ◦C. The siRNA used
were two ABCC1 siRNA (siRNA id: SASI_Hs02_00338730 and SASI_Hs02_00338731, referred to as
#30 and #31, respectively) (Gene id: 4363) and 2 ABCC4 siRNA (siRNA id: SASI_Hs02_00324134 and
SASI_Hs02_00324135, referred to as #34 and #35, respectively) (Gene id: 10257) (Merck). A negative
control siRNA (Merck) was used to distinguish sequence-specific silencing from nonspecific effects.
4.7. Whole Cell Lysates
Harvested cells were placed on ice. Three hundred to four hundred microliters of ice-cold lysis
buffer (0.15-M NaCl, 0.05-M Tris, pH 8.0, 1% (v/v) Triton-X100, 1-mM EDTA, and 1-mM pepstatin,
1.3-mM benzamidine, and 1.8-mM leupeptin) was added to the cells. The cells were resuspended
by vortexing. The cell suspension obtained was kept on ice and vortexed every 10 min for 1 h.
Cells suspension were then centrifuged for 15 min at 15,600× g at 4 ◦C, and the supernatant containing
the whole cell lysate was quantified for total protein concentrations using a bicinchoninic acid kit
(Pierce, ThermoFisher Scientific). The samples were mixed with sample buffer for loading on sodium
dodecyl sulphate (SDS) gels.
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4.8. Cell Membrane Extraction
Cell pellets harvested and resuspended in 20 mL of homogenization buffer (50-mM Tris, pH 7.4,
250-mM sucrose, and 0.25-mM CaCl2) containing protease inhibitors (1-mM pepstatin, 1.3-mM
benzamidine, and 1.8-mM leupeptin). All the subsequent steps were done on ice. The cell suspension
was then placed in the cell disruption vessel for nitrogen cavitation at 500 psi (Model 4639 Parr Cell
Disruption Vessels (Parr®)). The vessel was incubated on ice for 15 min. Pressure was released slowly,
and sample collected dropwise and centrifuged for 10 min at 560× g at 4 ◦C. The supernatant was
collected, and the pellet, which contained unbroken cells and debris, was discarded. The supernatant
was then ultracentrifuged at 100,000× g at 4 ◦C for 20 min. The supernatant was carefully discarded
and the membrane pellet resuspended in 0.5–1-mL Tris sucrose buffer (TSB) (50-mM Tris-HCl,
pH 7.4, and 0.25-mM sucrose). A needle syringe (0.45 mm × 13 mm) was used to resuspend the
membrane proteins in TSB. Protein concentration was determined using a bicinchoninic acid kit (Pierce,
ThermoFisher). Samples were kept on ice during the membrane preparations and were mixed with a
sample buffer for loading on sodium dodecyl sulphate (SDS) gels.
4.9. RNA Isolation and Quantitative Real-Time (RT-qPCR)
The total RNA from MDA-MB-231 and MCF-7 cells, respectively, was extracted using a Bioline
ISOLATE RNA mini kit according to the manufacturer’s protocol (Meridian Biosciences, London, UK).
The quantity of the isolated RNA obtained was measured using a NanoDrop™ 1000 spectrophotometer
(Thermo Fisher Scientific), and samples were stored at −80 ◦C. mRNA (600 ng) was reverse-transcribed
to cDNA using a Precision NanoScript™ 2 Reverse Transcription kit (Primerdesign, Chandlers Ford,
UK) according to the manufacturer’s protocol. The samples were then placed in a thermocycler, which
was set for 20 min at 42 ◦C, 10 min at 75 ◦C, and holding at 4 ◦C. The cDNA samples obtained were
diluted 1 in 10 with RNase/DNase-free water and stored at −20 ◦C.
The cDNA samples were amplified in qPCR using the Thermo Scientific PiKoReal 96 Real-Time
PCR system. For one reaction, a master mix containing 10 µL of PrecisionPlus™ 2 × qPCR Mastermix
with Sybr green with inert blue dye (Primerdesign), 1 µL of the reverse primer, 1 µL of the forward
primer, and 3 µL of RNase/DNase-free water was prepared. Five microliters of cDNA were first
added to each well of a 96-well Piko PCR plate in triplicate, followed by 15 µL of the master mix,
ensuring that no bubbles were formed in the wells. The expression levels were normalized to
human β-actin and human GAPDH as the house keeping genes. RNase/DNase-free water was
used as the negative control. The PCR primers were used as follow: β-actin forward nucleotide:
5′-CTGGAACGGTGAAGGTGACA-3′, reverse nucleotide: 5′-AAGGGACTTCCTGTAACAATGCA-3′;
GAPDH forward nucleotide: 5′-TGCACCACCAACTGCTTAGC-3′, reverse nucleotide: 5′-GGCATG
GACTGTGGTCATGAG-3′; ABCC1 forward nucleotide 5′-CGACATGACCGAGGCTACATT-3′,
reverse nucleotide 5′-AGCAGACGATCCACAGCAAAA-3′; and ABCC4 forward nucleotide
5′-TGTGGCTTTGAACACAGCGTA-3′, reverse nucleotide 5′-CCAGCACACTGAACGTGATAA-3′.
The qPCR data were analyzed using the double-delta Ct analysis. Each reaction was performed
three times.
4.10. Western Blotting
For Western blot analysis, the total protein samples (80 µg/well) were loaded and separated by
SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis), then transferred to a PVDF
membrane. The membrane was blocked in blocking buffer (5% w/v BSA in Tris-buffered saline (25-mM
Tris, pH 7.4, 150-mM NaCl, and 0.05% Tween 20) (TBS-T) for 1 h at room temperature, then incubated
in appropriate primary antibodies for 1 h at room temperature or overnight at 4 ◦C. The primary
antibodies used were: anti-ABCC1 derived in rabbit (1:1000, EPR4658(2); Abcam), anti-ABCC4 derived
in rat (1:100, M4I-10; Abcam), anti-ABCB1 derived in mouse (1:200; Thermo Fisher), anti-ABCG2
derived in mouse (1:50, Bxp1; Santa Cruz, Heidelberg, Germany), or anti-GPR55 (rabbit) (1:100;
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Abcam). The secondary antibodies used were anti-rabbit HRP (1:3000; Cell Signaling Technology,
Leiden, The Netherlands), anti-rat HRP (1:5000; Merck), and anti-mouse HRP (1:4000; Cell Signaling
Technology). Blots were visualized using a SuperSignal West Chemiluminescent kit (Pierce, Thermo
Fisher) and the Li-Cor C-Digit blot scanner, and the images were analyzed using the Image Studio
Lite software imaging system (Li-Cor, Cambridge, UK). Afterwards, blots were re-probed using
anti-α-tubulin (mouse) (1:1000; Merck) to check for equal sample loading. Western blot analysis was
repeated at least 3 times for each experiment.
4.11. ELISA
Following siRNA knockdown, to determine the levels of molecules exported from cells, ELISAs
were carried out on the media. As a control, 3 wells of nontransfected cells were treated with 50-µM
MK571. For cAMP, cells were first stimulated with 100-µM forskolin for 2 h at 37 ◦C. For PGE2, cells
were stimulated with 10-µg/mL lipopolysaccharides (LPS) for 24 h at 37 ◦C and with 80-nM phorbol
12-myristate 13-acetate (PMA) for 1 h at 37 ◦C, respectively. For S1P, there was no stimulation. The cell
culture medium was then replaced with a fresh cell culture medium, and the cells were incubated for
18 h at 37 ◦C. The supernatants (conditioned media) were centrifuged at 1000× g to pellet out any
floating cells and collected and stored at −80 ◦C or used immediately for determination of cAMP by
using the cAMP ELISA kit (Enzo Life Sciences Inc., Exeter, UK), for the determination of PGE2, using
the PGE2 ELISA kit (Enzo Life Sciences Inc.), or for S1P, using the human S1P ELISA kit (Abbexa
Ltd., Cambridge, UK), according to the manufacturer’s instructions. The cells were also harvested for
protein quantification.
4.12. Statistical Analysis
Statistical analysis of data was carried out using GraphPad Prism 8.1 (San Diego, CA, USA).
For multiple comparisons with one independent variable, a one-way ANOVA was used with Dunnett’s
post-hoc test. For multiple comparisons with two independent variables, a two-way ANOVA was
used with Dunnett’s post-hoc test. A value of p < 0.05 was considered significant.
5. Conclusions
In summary, our results show that ABCC1 plays a role in breast cancer proliferation, whilst
ABCC4 has a greater role in cellular migration and invasion. It may well be that both transporters
are important; their overlapping substrate specificity means they can likely compensate for each
other. The mechanism by which these transporters (and others) are involved in the development and
progression of breast cancer needs to be investigated further. It is key to know exactly how they are
involved before they can be considered as targets for treatment.
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Abbreviations
ABC ATP-Binding Cassette
ATP Adenosine triphosphate
ABCB1 ABC B subfamily member 1/P-glycoprotein
ABCC1 ABC C subfamily member 1/Multidrug resistance protein 1
ABCC4 ABC C subfamily member 4/Multidrug resistance protein 4
ABCG2 ABC G subfamily member 2/Breast cancer resistance protein
ANOVA Analysis of variance
BSA Bovine serum albumin
cAMP cyclic adenosine monophosphate
cGMP cyclic guanosine monophosphate
DMSO dimethylsulfoxide
ELISA Enzyme-linked immunoadsorbant assay
MCF-7 Michigan cancer foundation 7 cell line
LPI Lysophosphatidyl inositol
MDA-MB-231 M.D. Anderson metastatic breast cancer cell line
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
mRNA messenger RNA
PCR Polymerase chain reaction
PGE2 prostaglandin E2
PVDF Polyvinylidene difluoride
SD Standard deviation
RT-qPCR Reverse transcription quantitative PCR
sem Standard error of the mean
S1P sphingosine 1 phosphate
siRNA small interfering RNA
SDS-PAGE SDS polyacrylamide gel electrophoresis
SYBR green
N′,N′-dimethyl-N-[4-[(E)-(3-methyl-1,3-benzothiazol-2-ylidene)methyl]-1-
phenylquinolin-1-ium-2-yl]-N-propylpropane-1,3-diamine
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